Clinical study of the therapeutic value of the Ulinastatin in systemic inflammatory response syndrome (SIRS)

Objective To observe the therapeutic value of the Ulinastatin in critical illness cases with SIRS by comparison between Ulinastatin group and no Ulinastatin groups. Methods The 48 SIRS patients according to the diagnosis criteria of SIRS were randomly divided into regular treatment group (group B) and Ulinastatin treatment group (group A). The efficacy of the therapy in both the groups were assessed and serum CRP, TNF-α,IL-6 and IL-10 levels were measured on admission and on the fifth day in both the group. Results SIRS markers all reduced more significantly in group A than in group B(P0.01). Serum CRP, TNF-α and IL-6 levels reduced more significantly in group A than in group B ( P 0.01). Serum CRP, TNF-α and IL-6 levels reduced more significantly after treatment in group A than in group B (P0.01). IL-10 rose significantly after treatment in group A(P0.05), but it didn't change significantly after treatment in group B ( P 0.05). Conclusion Ulinastatin improved significantly the clinical effects of SIRS, prevented the MODS incidence, prohibited the inflammatory cytokinases and raised the anti-inflammatory cytokinases in the treatment of SIRS. [